INTRODUCTION: In this study we describe a patient with a prolonged myasthenic crisis refractory to conventional immunomodulatory therapy who was treated with GM-CSF (granulocyte macrophage colony-stimulating factor, sargramostim). METHODS: T-regulatory cell (Treg) suppressive function and Foxp3 expression were evaluated before and after treatment with GM-CSF. RESULTS: Treatment with GM-CSF was associated with clinical improvement, expansion in the circulating numbers of Foxp3(+) cells, increase in Foxp3 expression levels in Tregs, early improvement in Treg suppressive capacity for AChR-α-induced T-cell proliferation, and subsequent enhancement in Treg suppression of polyclonal T-cell proliferation. CONCLUSION: Although definitive conclusions cannot be drawn from a single case, the correlation with similar findings in GM-CSF-treated animals with experimental autoimmune myasthenia gravis suggests further exploration of the effects of GM-CSF in myasthenia gravis should be studied in a clinical trial setting.
INTRODUCTION: In this study we describe a patient with a prolonged myasthenic crisis refractory to conventional immunomodulatory therapy who was treated with GM-CSF (granulocyte macrophage colony-stimulating factor, sargramostim). METHODS: T-regulatory cell (Treg) suppressive function and Foxp3 expression were evaluated before and after treatment with GM-CSF. RESULTS: Treatment with GM-CSF was associated with clinical improvement, expansion in the circulating numbers of Foxp3(+) cells, increase in Foxp3 expression levels in Tregs, early improvement in Treg suppressive capacity for AChR-α-induced T-cell proliferation, and subsequent enhancement in Treg suppression of polyclonal T-cell proliferation. CONCLUSION: Although definitive conclusions cannot be drawn from a single case, the correlation with similar findings in GM-CSF-treated animals with experimental autoimmune myasthenia gravis suggests further exploration of the effects of GM-CSF in myasthenia gravis should be studied in a clinical trial setting.
Authors: Jian Rong Sheng; Liangcheng Li; Balaji B Ganesh; Chenthamarakshan Vasu; Bellur S Prabhakar; Matthew N Meriggioli Journal: J Immunol Date: 2006-10-15 Impact factor: 5.422
Authors: S Brocke; C Brautbar; L Steinman; O Abramsky; J Rothbard; D Neumann; S Fuchs; E Mozes Journal: J Clin Invest Date: 1988-12 Impact factor: 14.808
Authors: Balaji B Ganesh; Donald M Cheatem; Jian Rong Sheng; Chenthamarakshan Vasu; Bellur S Prabhakar Journal: Int Immunol Date: 2009-01-27 Impact factor: 4.823
Authors: Jian Rong Sheng; Liang Cheng Li; Balaji B Ganesh; Bellur S Prabhakar; Matthew N Meriggioli Journal: Clin Immunol Date: 2008-05-27 Impact factor: 3.969
Authors: Lisa M Kosloski; Elizabeth A Kosmacek; Katherine E Olson; R Lee Mosley; Howard E Gendelman Journal: J Neuroimmunol Date: 2013-10-29 Impact factor: 3.478
Authors: Muthusamy Thiruppathi; Julie Rowin; Qin Li Jiang; Jian Rong Sheng; Bellur S Prabhakar; Matthew N Meriggioli Journal: Ann N Y Acad Sci Date: 2012-12 Impact factor: 5.691